Health-related quality of life assessment in trials testing tyrosine kinase inhibitors or immune checkpoints inhibitors in early-stage NSCLC
Our systematic evaluation revealed suboptimal evaluation and underreporting of HRQoL in patients treated with novel agents and combinations in resectable NSCLC. Systematic evaluation and reporting of HRQoL should be prioritized in future trials.
Authors
- Massimo Di Maïo (ORCID: https://orcid.org/0000-0001-8906-3785)
- Oriana Ciani (ORCID: https://orcid.org/0000-0002-3607-0508)
- Cecilia Pompili (ORCID: https://orcid.org/0000-0001-6746-5441)
- Fabio Salomone (ORCID: https://orcid.org/0000-0001-7706-1803)
- Narjust Florez (ORCID: https://orcid.org/0009-0004-0806-6722)
- Alberto Servetto (ORCID: https://orcid.org/0000-0003-3624-224X)
- Roberto Ferrara (ORCID: https://orcid.org/0000-0001-6443-5642)
- Gabriella Pravettoni (ORCID: https://orcid.org/0000-0002-9135-2938)
- Giorgia Novero
Institutions
- Vita-Salute San Raffaele University (IT)
- University of Milan (IT)
- University of Hull (GB)
- Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT)
- Fondazione Ricerca Molinette (IT)
- Dana-Farber Cancer Institute (US)
- Department of Medical Sciences (BY)
- IRCCS Ospedale San Raffaele (IT)
- University of Turin (IT)
- European Institute of Oncology (IT)
- Bocconi University (IT)
- University of Naples Federico II (IT)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1093/oncolo/oyaf339
- Primary Topic
- Multiple and Secondary Primary Cancers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Exelixis
- BeiGene
- Daiichi-Sankyo
- Eisai
- Astellas Pharma
- Medela
- Ipsen
- Genentech